Everence Capital Management Inc. Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Everence Capital Management Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 34,790 shares of the biopharmaceutical company’s stock after acquiring an additional 530 shares during the period. Everence Capital Management Inc.’s holdings in Gilead Sciences were worth $3,214,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. nVerses Capital LLC acquired a new position in Gilead Sciences in the third quarter valued at $25,000. Valued Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. Cedar Wealth Management LLC grew its holdings in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the period. Finally, Friedenthal Financial acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $50,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock valued at $41,902,086 over the last three months. Insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Oppenheimer lifted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Mizuho increased their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Royal Bank of Canada restated a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Bank of America reiterated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday, December 10th. Twelve research analysts have rated the stock with a hold rating, twelve have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Gilead Sciences Price Performance

Gilead Sciences stock traded up $0.10 during trading hours on Friday, hitting $91.98. 927,709 shares of the company traded hands, compared to its average volume of 2,145,055. The firm’s 50-day simple moving average is $91.76 and its two-hundred day simple moving average is $82.22. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $114.63 billion, a P/E ratio of 1,022.00, a P/E/G ratio of 2.38 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.